Mylan files suit against FDA to overturn Provigil decision
Mylan alleges Teva did not keep up valid paragraph IV certifications as a result of its purchase of Cephalon and the FDA should have found Mylan as the
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.